299 related articles for article (PubMed ID: 10976692)
1. The separation of benign and malignant mesothelial proliferations.
Churg A; Colby TV; Cagle P; Corson J; Gibbs AR; Gilks B; Grimes M; Hammar S; Roggli V; Travis WD
Am J Surg Pathol; 2000 Sep; 24(9):1183-200. PubMed ID: 10976692
[TBL] [Abstract][Full Text] [Related]
2. Differential diagnosis of benign and malignant mesothelial proliferations on pleural biopsies.
Cagle PT; Churg A
Arch Pathol Lab Med; 2005 Nov; 129(11):1421-7. PubMed ID: 16253023
[TBL] [Abstract][Full Text] [Related]
3. New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
Churg A; Sheffield BS; Galateau-Salle F
Arch Pathol Lab Med; 2016 Apr; 140(4):318-21. PubMed ID: 26288396
[TBL] [Abstract][Full Text] [Related]
4. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
5. The separation of benign and malignant mesothelial proliferations.
Churg A; Galateau-Salle F
Arch Pathol Lab Med; 2012 Oct; 136(10):1217-26. PubMed ID: 23020727
[TBL] [Abstract][Full Text] [Related]
6. β-catenin expression in benign and malignant pleural disorders.
Anani W; Bruggeman R; Zander DS
Int J Clin Exp Pathol; 2011; 4(8):742-7. PubMed ID: 22135721
[TBL] [Abstract][Full Text] [Related]
7. Keratin and epithelial membrane antigen immunoreactivity in nonneoplastic fibrous pleural lesions: implications for the diagnosis of desmoplastic mesothelioma.
Epstein JI; Budin RE
Hum Pathol; 1986 May; 17(5):514-9. PubMed ID: 2422109
[TBL] [Abstract][Full Text] [Related]
8. Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations.
Shivapurkar N; Wiethege T; Wistuba II; Salomon E; Milchgrub S; Muller KM; Churg A; Pass H; Gazdar AF
J Cell Biochem; 1999 Dec; 76(2):181-8. PubMed ID: 10618635
[TBL] [Abstract][Full Text] [Related]
9. Malignant mesothelioma eight years after a diagnosis of atypical mesothelial hyperplasia.
Scurry J; Duggan MA
J Clin Pathol; 1999 Jul; 52(7):535-7. PubMed ID: 10605410
[TBL] [Abstract][Full Text] [Related]
10. Cyclin D1 immunohistochemical staining to separate benign from malignant mesothelial proliferations.
Pors J; Naso J; Berg K; Churg A
Mod Pathol; 2020 Feb; 33(2):312-318. PubMed ID: 31685964
[TBL] [Abstract][Full Text] [Related]
11. UHRF1 Immunohistochemical Staining Separates Benign Reactive Spindle Cell Mesothelial Proliferations From Sarcomatoid Mesotheliomas.
Yang H; Cheung S; Churg A
Am J Surg Pathol; 2022 Jun; 46(6):840-845. PubMed ID: 34772842
[TBL] [Abstract][Full Text] [Related]
12. The fake fat phenomenon in organizing pleuritis: a source of confusion with desmoplastic malignant mesotheliomas.
Churg A; Cagle P; Colby TV; Corson JM; Gibbs AR; Hammar S; Ordonez N; Roggli VL; Tazelaar HD; Travis WD; Wick M;
Am J Surg Pathol; 2011 Dec; 35(12):1823-9. PubMed ID: 21959310
[TBL] [Abstract][Full Text] [Related]
13. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation.
Shi M; Fraire AE; Chu P; Cornejo K; Woda BA; Dresser K; Rock KL; Jiang Z
Am J Surg Pathol; 2011 Jun; 35(6):878-82. PubMed ID: 21566519
[TBL] [Abstract][Full Text] [Related]
14. Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive Mesothelial Cells With FISH Analysis of p16.
Hiroshima K; Wu D; Hasegawa M; Koh E; Sekine Y; Ozaki D; Yusa T; Walts AE; Marchevsky AM; Nabeshima K; Tada Y; Shimada H; Tagawa M
Diagn Cytopathol; 2016 Jul; 44(7):591-8. PubMed ID: 27079839
[TBL] [Abstract][Full Text] [Related]
15. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
16. [Differential diagnosis of preneoplastic lesions of the pleura and of early mesothelioma: immunohistochemical and morphological findings].
Krismann M; Thattamparambil P; Simon F; Johnen G
Pathologe; 2006 Mar; 27(2):99-105. PubMed ID: 16435096
[TBL] [Abstract][Full Text] [Related]
17. Use of Programmed Death Ligand-1 (PD-L1) Staining to Separate Sarcomatoid Malignant Mesotheliomas From Benign Mesothelial Reactions.
Derakhshan F; Ionescu D; Cheung S; Churg A
Arch Pathol Lab Med; 2020 Feb; 144(2):185-188. PubMed ID: 31484000
[TBL] [Abstract][Full Text] [Related]
18. Pathohistological diagnosis and differential diagnosis.
Tischoff I; Neid M; Neumann V; Tannapfel A
Recent Results Cancer Res; 2011; 189():57-78. PubMed ID: 21479896
[TBL] [Abstract][Full Text] [Related]
19. Interpretation of pleural biopsy specimens and aspirates with the immunoperoxidase technique.
Herbert A; Gallagher PJ
Thorax; 1982 Nov; 37(11):822-7. PubMed ID: 6761889
[TBL] [Abstract][Full Text] [Related]
20. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]